Sepsis is an immune response to a microbial invasion that causes organ injury and dysfunction due to a systemic inflammatory response. Sepsis is a serious, life-threatening condition and a widely recognized global health challenge. Given its high death rate, it is critical to diagnose sepsis and start treatment as early as possible. There is an urgent need for a sensitive and rapid screening method for detecting sepsis. In this study, we investigated the use of MMP-9 as a biomarker for sepsis. A colorimetric paper-based biosensor was used for the detection of MMP-9 utilizing peptide-magnetic nanoparticle conjugates. The method is based on the cleavage of the MMP-9-specific peptide by the protease leading to the detaching of the magnetic beads from the sensor surface and changing of color. A fecal intraperitoneal (FIP) challenge was used to induce sepsis in mice, and an MMP-9 secretion was measured by taking blood and Bronchoalveolar Lavage (BAL) fluid samples at 1 h, 2 h, 4 h, and 20 h (early sepsis) post-challenge intervals. The results of the paper-based sensor for the detection of MMP-9 levels in blood samples and BAL samples were compared with ELISA and Western Blot. We found that both blood and BAL levels of MMP-9 increased immediately and could be detected as early as 1 h in FIP mice post-challenge. Our work adds evidence to the assertion that MMP-9 is a reliable biomarker for the detection of sepsis at early stages.

Evidence shows that the risk perception of humans can significantly affect their response to a threat. This population-based, cross-sectional study explored the determinants of perceived disease seriousness, perceived disease infectiveness, and perceived prevention self-efficacy of coronavirus disease (COVID-19), during the lockdown period, using the health belief model for preventive behavior (HBMPB) among 4423 adults in Saudi Arabia from 13 provinces. Multivariate binary regression was used to analyze the independent factors of three risk perception variables and to measure their effect on adherence to preventive measures. Overall, COVID-19 seriousness was perceived to be higher than that of diabetes and lower than that of a heart attack, while its infectiousness was perceived to be high by 75.3% of the participants. Furthermore, 66.6% had a low perception of their prevention self-efficacy. The HBMPB showed independent effects of all three risk perception parameters on adherence to the preventive measures, including perceived seriousness (Odd’s ratio [OR] = 1.26; 95% confidence interval [95% CI] = 1.01–1.56), infectiousness (OR = 1.90; 95% CI = 1.52–2.38), and prevention self-efficacy (OR = 1.51; 95% CI = 1.20–1.91). Authorities should maintain an optimal level of communication on the COVID-19 risk, communicate more about the virus’ cycle and the disease to demystify the rationale of the preventive measures, and enhance confidence in their efficiency.

Antibiotic resistance poses a growing threat to public health, yet limited innovation and development of new antibacterial agents continue to hinder antibiotic discovery. Although only a few novel antibiotic candidates have passed clinical trials and reached the market, resistance continues to grow faster than antibiotic development. Despite numerous advances in drug development, using these technologies in isolation has constrained antibiotic discovery. This review examines how advanced technologies integrate into antibiotic drug discovery. It highlights a coupled approach (co-applied technologies) as an innovative strategy to mitigate the limitations of single approaches and accelerate lead discovery. By highlighting each technology and reviewing its potential applications, this strategy opens new routes and methods that can yield novel chemical scaffolds and new mechanisms of action (i.e., weakening microbial resistance), addressing the challenges posed by increasing global resistance and shortcomings in current antibiotic development. The review also addresses the challenges and barriers to discovering next-generation antibiotics. It also encourages researchers to implement platforms that combine coupled approaches and technologies, such as computational, genomic, biochemical, and structural tools, to replenish the next-generation antibiotic discovery pipeline and address the antimicrobial resistance (AMR) crisis. To strengthen global efforts and lessen the AMR crisis, an innovative antibiotic discovery strategy is necessary.